Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

312
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
312
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

382
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
382
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

451
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
451
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

750
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
750
Methods of Documentation II: POMR01:26

Methods of Documentation II: POMR

1.5K
The Problem-Oriented Medical Record (POMR) revolutionized medical record-keeping by introducing a systematic approach focusing on the patient's problems rather than merely listing symptoms. Dr. Lawrence Weed's introduction of this method in the 1960s marked a significant advancement in medical documentation. The POMR framework consists of four key components: the database, problem list, plan of care, and progress notes.
1.5K
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

409
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
409

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Lancet regional health. Americas·2026
Same author

Expert Validation of an Artificial Intelligence-Enabled Trial Matching Solution Using Real-World Data From Patients With Cancer.

JCO oncology practice·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Blood advances·2026
Same author

A State Blueprint to Equip Schools With a Uniform Overdose Response Strategy.

Pediatrics·2026
Same author

Pharmacy and transfusion costs of ruxolitinib and momelotinib in patients with myelofibrosis and anemia.

Leukemia & lymphoma·2026

Related Experiment Video

Updated: Feb 22, 2026

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.5K

Approach to MPN Symptom Assessment.

Holly Geyer1, Ruben A Mesa2

  • 1Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.

Current Hematologic Malignancy Reports
|September 25, 2017
PubMed
Summary

Myeloproliferative neoplasms (MPNs) cause significant symptoms. Patient Reported Outcome (PRO) tools effectively assess MPN symptom burden and are crucial for clinical practice and treatment guidelines.

Keywords:
Essential thrombocythemiaMPN-SAFMyelofibrosisMyeloproliferative neoplasmPolycythemia veraSymptom

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K
Isolation and Characterization of Neutrophil-derived Microparticles for Functional Studies
06:56

Isolation and Characterization of Neutrophil-derived Microparticles for Functional Studies

Published on: March 2, 2018

10.9K

Related Experiment Videos

Last Updated: Feb 22, 2026

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.5K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K
Isolation and Characterization of Neutrophil-derived Microparticles for Functional Studies
06:56

Isolation and Characterization of Neutrophil-derived Microparticles for Functional Studies

Published on: March 2, 2018

10.9K

Area of Science:

  • Hematology
  • Oncology
  • Patient-Reported Outcomes

Background:

  • Myeloproliferative neoplasms (MPNs) are associated with substantial symptom burden.
  • Traditional measures of disease burden often do not correlate with patient-reported symptoms.

Purpose of the Study:

  • To review the complexity of symptom burden in MPNs.
  • To explore the integration of validated MPN Patient Reported Outcome (PRO) tools into clinical practice for symptom assessment.

Main Methods:

  • Literature review focusing on MPN symptom burden and PRO tool utilization.
  • Analysis of current clinical practice and guideline integration of PROs.

Main Results:

  • MPN symptom burden is heterogeneous and not always captured by standard metrics.
  • Validated MPN PRO tools offer precise and rapid assessment of symptoms.
  • PRO tools enhance understanding of treatment impact on patient experience.

Conclusions:

  • MPN PRO tools are essential for accurate symptom burden assessment.
  • PROs are integral to National Comprehensive Cancer Network (NCCN) guidelines for MPN management.
  • Regular use of PRO tools in clinical practice is recommended for improved patient care.